| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30dca8e5a7d2a4a0b9f5e7dd8a129750 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_569f35beb10bf38ab36af752173a0f40 |
| publicationDate |
2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021195661-A1 |
| titleOfInvention |
Anti-viral compounds and methods for administration thereof |
| abstract |
This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS~CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drags formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations that are incorporated into pulmonary and oral delivery systems. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023075714-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11780844-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11613553-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11701372-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660307-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023095075-A1 |
| priorityDate |
2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |